NASDAQ:PTIProteostasis Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Proteostasis Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.32 -0.09 (-6.38 %) (As of 08/11/2020 04:00 PM ET) Add Compare Share Today's Range$1.31Now: $1.32▼$1.4350-Day Range$1.27MA: $1.42▼$1.7652-Week Range$0.61Now: $1.32▼$4.72Volume1.28 million shsAverage Volume1.27 million shsMarket Capitalization$68.87 millionP/E RatioN/ADividend YieldN/ABeta1.19 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingProteostasis Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.20, Proteostasis Therapeutics has a potential upside of 293.9% from its current price of $1.32.Amount of Analyst CoverageProteostasis Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.1 Community Rank Outperform VotesProteostasis Therapeutics has received 312 “outperform” votes. (Add your “outperform” vote.)Underperform VotesProteostasis Therapeutics has received 440 “underperform” votes. (Add your “underperform” vote.)Community SentimentProteostasis Therapeutics has received 58.51% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Proteostasis Therapeutics and other stocks. Vote “Outperform” if you believe PTI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PTI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldProteostasis Therapeutics does not currently pay a dividend.Dividend GrowthProteostasis Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Proteostasis Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.80% of the stock of Proteostasis Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 21.14% of the stock of Proteostasis Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Proteostasis Therapeutics are expected to decrease in the coming year, from ($0.91) to ($0.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Proteostasis Therapeutics is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Proteostasis Therapeutics is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProteostasis Therapeutics has a P/B Ratio of 1.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.10 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PTI Previous Symbol CUSIPN/A CIK1445283 Webwww.proteostasis.com Phone617-225-0096Debt Debt-to-Equity Ratio0.25 Current Ratio6.69 Quick Ratio6.69Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5 million Price / Sales13.77 Cash FlowN/A Price / Cash FlowN/A Book Value$1.22 per share Price / Book1.08Profitability EPS (Most Recent Fiscal Year)($1.16) Net Income$-59,130,000.00 Net MarginsN/A Return on Equity-75.39% Return on Assets-55.04%Miscellaneous Employees44 Outstanding Shares52,176,000Market Cap$68.87 million Next Earnings Date11/5/2020 (Estimated) OptionableOptionable $1.32 -0.09 (-6.38 %) (As of 08/11/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive PTI News and Ratings via Email Sign-up to receive the latest news and ratings for PTI and its competitors with MarketBeat's FREE daily newsletter. Proteostasis Therapeutics (NASDAQ:PTI) Frequently Asked Questions How has Proteostasis Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Proteostasis Therapeutics' stock was trading at $1.16 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PTI stock has increased by 13.8% and is now trading at $1.32. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Proteostasis Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proteostasis Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Proteostasis Therapeutics. When is Proteostasis Therapeutics' next earnings date? Proteostasis Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Proteostasis Therapeutics. How were Proteostasis Therapeutics' earnings last quarter? Proteostasis Therapeutics Inc (NASDAQ:PTI) announced its quarterly earnings results on Thursday, August, 6th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.04. View Proteostasis Therapeutics' earnings history. What price target have analysts set for PTI? 5 equities research analysts have issued 12 month price targets for Proteostasis Therapeutics' stock. Their forecasts range from $3.00 to $8.00. On average, they expect Proteostasis Therapeutics' stock price to reach $5.20 in the next year. This suggests a possible upside of 293.9% from the stock's current price. View analysts' price targets for Proteostasis Therapeutics. Has Proteostasis Therapeutics been receiving favorable news coverage? News headlines about PTI stock have trended very positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Proteostasis Therapeutics earned a coverage optimism score of 3.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Proteostasis Therapeutics. Are investors shorting Proteostasis Therapeutics? Proteostasis Therapeutics saw a drop in short interest in July. As of July 31st, there was short interest totaling 2,530,000 shares, a drop of 5.6% from the July 15th total of 2,680,000 shares. Based on an average daily trading volume, of 1,110,000 shares, the short-interest ratio is presently 2.3 days. Approximately 6.0% of the company's shares are sold short. View Proteostasis Therapeutics' Short Interest. Who are some of Proteostasis Therapeutics' key competitors? Some companies that are related to Proteostasis Therapeutics include Bicycle Therapeutics (BCYC), Spero Therapeutics (SPRO), Menlo Therapeutics (MNLO), MediciNova (MNOV), Affimed (AFMD), NextCure (NXTC), Ritter Pharmaceuticals (RTTR), Northwest Biotherapeutics (NWBO), Urovant Sciences (UROV), Verastem (VSTM), Lannett (LCI), Arbutus Biopharma (ABUS), Fortress Biotech (FBIO), Abeona Therapeutics (ABEO) and IDEAYA Biosciences (IDYA). View all competitors. What other stocks do shareholders of Proteostasis Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Proteostasis Therapeutics investors own include Idera Pharmaceuticals (IDRA), BHP Group (BHP), Sorrento Therapeutics (SRNE), Paratek Pharmaceuticals (PRTK), Opko Health (OPK), Amarin (AMRN), Rite Aid (RAD), VBI Vaccines (VBIV), Micron Technology (MU) and SCYNEXIS (SCYX). Who are Proteostasis Therapeutics' key executives? Proteostasis Therapeutics' management team includes the following people: Ms. Meenu Chhabra, Pres, CEO, Interim Principal Financial & Accounting Officer and Director (Age 48, Pay $844.78k)Ms. Sheila Gilbride Wilson M.B.A., Chief Operating Officer (Age 62, Pay $521.96k)Dr. Po-Shun Lee, Consultant (Age 51, Pay $545.85k)Dr. Marija Zecevic, Chief Commercial Officer (Age 46, Pay $530.46k)Dr. Benito Munoz, Chief Scientific Officer (Age 58) When did Proteostasis Therapeutics IPO? (PTI) raised $51 million in an initial public offering (IPO) on Thursday, February 11th 2016. The company issued 3,900,000 shares at a price of $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers. What is Proteostasis Therapeutics' stock symbol? Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI." Who are Proteostasis Therapeutics' major shareholders? Proteostasis Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include WINTON GROUP Ltd (1.58%) and Virtu Financial LLC (0.07%). Company insiders that own Proteostasis Therapeutics stock include Enterprise Associates 12 New, Franklin M Berger, Meenu Chhabra and Po Shun Lee. View institutional ownership trends for Proteostasis Therapeutics. Which major investors are buying Proteostasis Therapeutics stock? PTI stock was bought by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, and Virtu Financial LLC. View insider buying and selling activity for Proteostasis Therapeutics. How do I buy shares of Proteostasis Therapeutics? Shares of PTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Proteostasis Therapeutics' stock price today? One share of PTI stock can currently be purchased for approximately $1.32. How big of a company is Proteostasis Therapeutics? Proteostasis Therapeutics has a market capitalization of $68.87 million and generates $5 million in revenue each year. The company earns $-59,130,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. Proteostasis Therapeutics employs 44 workers across the globe. What is Proteostasis Therapeutics' official website? The official website for Proteostasis Therapeutics is www.proteostasis.com. How can I contact Proteostasis Therapeutics? Proteostasis Therapeutics' mailing address is 80 Guest Street Suite 500, Boston MA, 02135. The company can be reached via phone at 617-225-0096 or via email at [email protected] This page was last updated on 8/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
